How have the trifecta of recent developments—associated, all-cause mortality reduction reported in ODYSSEY Outcomes, price reduction of PCSK9 inhibitors, and new AHA Guidelines—affected your approach to deploying these agents at the front lines?

Name: How have the trifecta of recent developments—associated, all-cause mortality reduction reported in ODYSSEY Outcomes, price reduction of PCSK9 inhibitors, and new AHA Guidelines—affected your approach to deploying these agents at the front lines?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Christian Ruff, MD

Christian Ruff, MD
Principal Investigator, ENGAGE-AF Trial
TIMI Group
Director, General Cardiology
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA